Deep sequencing: Becoming a critical tool in clinical virology

Journal of Clinical Virology

Volumn 61, Issue 1, 2014, Pages 9-19

  Quiñones Mateu, Miguel E ^a,b   Avila, Santiago ^c,d   Reyes Teran, Gustavo ^c,d   Martinez, Miguel A ^e  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^d Centro de Investigaciones en Enfermedades Infecciosas   (Mexico)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Deep sequencing; Hepatitis C virus (HCV); Human immunodeficiency virus (HIV); Influenza virus; Next generation sequencing (NGS)

Indexed keywords

DEEP SEQUENCING; DNA SEQUENCE; HEPATITIS C VIRUS; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRAL TROPISM; VIRUS GENOME; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; CLASSIFICATION; GENETIC VARIABILITY; GENETICS; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; ISOLATION AND PURIFICATION; MOLECULAR DIAGNOSIS; PROCEDURES; TRENDS; VIROLOGY; VIRUS;

GENETIC VARIATION; HEPATITIS C, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HUMANS; INFLUENZA, HUMAN; MOLECULAR DIAGNOSTIC TECHNIQUES; VIROLOGY; VIRUSES;

EID: 84905098081     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.06.013     Document Type: Review

References (252)

1. Holley R.W., Apgar J., Everett G.A., Madison J.T., Marquisee M., Merrill S.H., et al. Structure of a ribonucleic acid. Science 1965, 147:1462-1465.
2. Maxam A.M., Gilbert W. A new method for sequencing DNA. Proc Natl Acad Sci USA 1977, 74:560-564.
3. Sanger F., Nicklen S., Coulson A.R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977, 74:5463-5467.
4. Baer R., Bankier A.T., Biggin M.D., Deininger P.L., Farrell P.J., Gibson T.J., et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 1984, 310:207-211.
5. Ratner L., Haseltine W., Patarca R., Livak K.J., Starcich B., Josephs S.F., et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985, 313:277-284.
6. Ronaghi M., Karamohamed S., Pettersson B., Uhlen M., Nyren P. Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem 1996, 242:84-89.
7. Brenner S., Johnson M., Bridgham J., Golda G., Lloyd D.H., Johnson D., et al. Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nat Biotechnol 2000, 18:630-634.
8. Loman N.J., Misra R.V., Dallman T.J., Constantinidou C., Gharbia S.E., Wain J., et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012.
9. Liu L., Li Y., Li S., Hu N., He Y., Pong R., et al. Comparison of next-generation sequencing systems. J Biotechnol 2012, 2012:251364.
10. Quail M.A., Smith M., Coupland P., Otto T.D., Harris S.R., Connor T.R., et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC genomics 2012, 13:341.
11. Margulies M., Egholm M., Altman W.E., Attiya S., Bader J.S., Bemben L.A., et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005, 437:376-380.
12. Bennett S. Solexa Ltd. Pharmacogenomics 2004, 5:433-438.
13. Valouev A., Ichikawa J., Tonthat T., Stuart J., Ranade S., Peckham H., et al. A high-resolution, nucleosome position map of C. elegans reveals a lack of universal sequence-dictated positioning. Genome Res 2008, 18:1051-1063.
14. Bowers J., Mitchell J., Beer E., Buzby P.R., Causey M., Efcavitch J.W., et al. Virtual terminator nucleotides for next-generation DNA sequencing. Nat Methods 2009, 6:593-595.
15. Rothberg J.M., Hinz W., Rearick T.M., Schultz J., Mileski W., Davey M., et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011, 475:348-352.
16. Eid J., Fehr A., Gray J., Luong K., Lyle J., Otto G., et al. Real-time sequencing from single polymerase molecules. Science 2009, 323:133-138.
17. Howorka S., Cheley S., Bayley H. Sequence-specific detection of individual DNA strands using engineered nanopores. Nat Biotechnol 2001, 19:636-639.
18. Radford A.D., Chapman D., Dixon L., Chantrey J., Darby A.C., Hall N. Application of next-generation sequencing technologies in virology. J Gen Virol 2012, 93:1853-1868.
19. Barzon L., Lavezzo E., Costanzi G., Franchin E., Toppo S., Palu G. Next-generation sequencing technologies in diagnostic virology. J Clin Virol 2013, 58:346-350.
20. Barba M., Czosnek H., Hadidi A. Historical perspective, development and applications of next-generation sequencing in plant virology. Viruses 2014, 6:106-136.
21. Gullapalli R.R., Lyons-Weiler M., Petrosko P., Dhir R., Becich M.J., LaFramboise W.A. Clinical integration of next-generation sequencing technology. Clin Lab Med 2012, 32:585-599.
22. Metzker M.L. Sequencing technologies - the next generation. Nat Rev 2010, 11:31-46.
23. Park J.Y., Kricka L.J., Fortina P. Next-generation sequencing in the clinic. Nat Biotechnol 2013, 31:990-992.
24. Gibson R.M., Schmotzer C.L., Quinones-Mateu M.E. Next-generation sequencing to help monitor patients infected with HIV: ready for clinical Use?. Curr Infect Dis Rep 2014, 16:401.
25. Quiñones-Mateu M.E., Endris V. The sequencing continuum for clinical research: from Sanger to next gen. Science 2014, 343:1159.
26. Archer J., Weber J., Henry K., Winner D., Gibson R., Lee L., et al. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PloS One 2012, 7:e49602.
27. Lipkin W.I., Firth C. Viral surveillance and discovery. Curr Opin Virol 2013, 3:199-204.
28. Mokili J.L., Rohwer F., Dutilh B.E. Metagenomics and future perspectives in virus discovery. Curr Opin Virol 2012, 2:63-77.
29. Julian T.R., Schwab K.J. Challenges in environmental detection of human viral pathogens. Curr Opin Virol 2012, 2:78-83.
30. Grard G., Fair J.N., Lee D., Slikas E., Steffen I., Muyembe J.J., et al. A novel rhabdovirus associated with acute hemorrhagic fever in central Africa. PLoS Pathog 2012, 8:e1002924.
31. Tan le V., van Doorn H.R., Nghia H.D., Chau T.T., Tu le T.P., de Vries M., et al. Identification of a new cyclovirus in cerebrospinal fluid of patients with acute central nervous system infections. mBio 2013, 4:e00213-e00231.
32. Lecuit M., Eloit M. The human virome: new tools and concepts. Trends Microbiol 2013, 21:510-515.
33. Delwart E. A roadmap to the human virome. PLoS Pathog 2013, 9:e1003146.
34. Minot S., Bryson A., Chehoud C., Wu G.D., Lewis J.D., Bushman F.D. Rapid evolution of the human gut virome. Proc Natl Acad Sci USA 2013, 110:12450-12455.
35. Minot S., Sinha R., Chen J., Li H., Keilbaugh S.A., Wu G.D., et al. The human gut virome: inter-individual variation and dynamic response to diet. Genome Res 2011, 21:1616-1625.
36. Foulongne V., Sauvage V., Hebert C., Dereure O., Cheval J., Gouilh M.A., et al. Human skin microbiota: high diversity of DNA viruses identified on the human skin by high throughput sequencing. PLoS One 2012, 7:e38499.
37. Li L., Deng X., Linsuwanon P., Bangsberg D., Bwana M.B., Hunt P., et al. AIDS alters the commensal plasma virome. J Virol 2013, 87:10912-10915.
38. Handley S.A., Thackray L.B., Zhao G., Presti R., Miller A.D., Droit L., et al. Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell 2012, 151:253-266.
39. De Vlaminck, Khush K.K., Strehl C., Kohli B., Luikart H., Neff N.F. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell 2013, 155:1178-1187.
40. Wylie K.M., Mihindukulasuriya K.A., Sodergren E., Weinstock G.M., Storch G.A. Sequence analysis of the human virome in febrile and afebrile children. PloS One 2012, 7:e27735.
41. Alquezar-Planas D.E., Mourier T., Bruhn C.A., Hansen A.J., Vitcetz S.N., Mork S., et al. Discovery of a divergent HPIV4 from respiratory secretions using second and third generation metagenomic sequencing. Sci Rep 2013, 3:2468.
42. Shan T., Li L., Simmonds P., Wang C., Moeser A., Delwart E. The fecal virome of pigs on a high-density farm. J Virol 2011, 85:11697-11708.
43. Bentley D.R., Balasubramanian S., Swerdlow H.P., Smith G.P., Milton J., Brown C.G., et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 2008, 456:53-59.
44. Phan T.G., Vo N.P., Boros A., Pankovics P., Reuter G., Li O.T., et al. The viruses of wild pigeon droppings. PloS One 2013, 8:e72787.
45. Day J.M., Ballard L.L., Duke M.V., Scheffler B.E., Zsak L. Metagenomic analysis of the turkey gut RNA virus community. Virol J 2010, 7:313.
46. Belak S., Karlsson O.E., Blomstrom A.L., Berg M., Granberg F. New viruses in veterinary medicine, detected by metagenomic approaches. Vet Microbiol 2013, 165:95-101.
47. Li L., Pesavento P.A., Shan T., Leutenegger C.M., Wang C., Delwart E. Viruses in diarrhoeic dogs include novel kobuviruses and sapoviruses. J Gen Virol 2011, 92:2534-2541.
48. Tong S., Zhu X., Li Y., Shi M., Zhang J., Bourgeois M., et al. New world bats harbor diverse influenza A viruses. PLoS Pathog 2013, 9:e1003657.
49. Quan P.L., Firth C., Conte J.M., Williams S.H., Zambrana-Torrelio C.M., Anthony S.J. Bats are a major natural reservoir for hepaciviruses and pegiviruses. Proc Natl Acad Sci USA 2013, 110:8194-8199.
50. Drexler J.F., Geipel A., Konig A., Corman V.M., van Riel D., Leijten L.M. Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes. Proc Natl Acad Sci USA 2013, 110:16151-16156.
51. Guo W.P., Lin X.D., Wang W., Tian J.H., Cong M.L., Zhang H.L., et al. Phylogeny and origins of hantaviruses harbored by bats, insectivores, and rodents. PLoS Pathog 2013, 9:e1003159.
52. Marsh G.A., de Jong C., Barr J.A., Tachedjian M., Smith C., Middleton D., et al. Cedar virus: a novel Henipavirus isolated from Australian bats. PLoS Pathog 2012, 8:e1002836.
53. Yang L., Wu Z., Ren X., Yang F., He G., Zhang J., et al. Novel SARS-like betacoronaviruses in bats, China, 2011. Emerg Infect Dis 2013, 19:989-991.
54. Smith I., Wang L.F. Bats and their virome: an important source of emerging viruses capable of infecting humans. Curr Opin Virol 2013, 3:84-91.
55. Leitner T. The Molecular Epidemiology of Human Viruses 2002, Springer, New York. 1st ed.
56. Hemelaar J. Implications of HIV diversity for the HIV-1 pandemic. J Infect 2013, 66:391-400.
57. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. Aids 2011, 25:679-689.
58. Lal R.B., Chakrabarti S., Yang C. Impact of genetic diversity of HIV-1 on diagnosis, antiretroviral therapy & vaccine development. Indian J Med Res 2005, 121:287-314.
59. Quinones-Mateu M.E., Arts E.J. Recombination in HIV-1: Update and implications. AIDS Rev 1999, 1:89-100.
60. Bruselles A., Rozera G., Bartolini B., Prosperi M., Del Nonno F., Narciso P. et al. Use of massive parallel pyrosequencing for near full-length characterization of a unique HIV Type 1 BF recombinant associated with a fatal primary infection. AIDS Res Hum Retroviruses 2009, 25:937-942.
61. Park S.Y., Goeken N., Lee H.J., Bolan R., Dube M.P., Lee H.Y. Developing high-throughput HIV incidence assay with pyrosequencing platform. J Virol 2014, 88:2977-2990.
62. Redd A.D., Quinn T.C., Tobian A.A. Frequency and implications of HIV superinfection. Lancet Infect Dis 2013, 13:622-628.
63. Smith D.B., Bukh J., Kuiken C., Muerhoff A.S., Rice C.M., Stapleton J.T., et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology 2014, 59:318-327.
64. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004, 85:3173-3188.
65. Simmonds P. The origin of hepatitis C virus. Curr Top Microbiol Immunol 2013, 369:1-15.
66. Newman R.M., Kuntzen T., Weiner B., Berical A., Charlebois P., Kuiken C. et al. Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants. J Infect Dis 2013, 208:17-31.
67. Forbi J.C., Purdy M.A., Campo D.S., Vaughan G., Dimitrova Z.E., Ganova-Raeva L.M., et al. Epidemic history of hepatitis C virus infection in two remote communities in Nigeria, West Africa. J Gen Virol 2012, 93:1410-1421.
68. Croville G., Soubies S.M., Barbieri J., Klopp C., Mariette J., Bouchez O. et al. Field monitoring of avian influenza viruses: whole-genome sequencing and tracking of neuraminidase evolution using 454 pyrosequencing. J Clin Microbiol 2012, 50:2881-2887.
69. Dugan V.G., Dunham E.J., Jin G., Sheng Z.M., Kaser E., Nolting J.M. et al. Phylogenetic analysis of low pathogenicity H5N1 and H7N3 influenza A virus isolates recovered from sentinel, free flying, wild mallards at one study site during 2006. Virology 2011, 417:98-105.
70. Marchenko V.Y., Alekseev A.Y., Sharshov K.A., Petrov V.N., Silko N.Y., Susloparov I.M., et al. Ecology of influenza virus in wild bird populations in Central Asia. Avian Dis 2012, 56:234-237.
71. Van Borm S., Rosseel T., Vangeluwe D., Vandenbussche F., van den Berg T., Lambrecht B. Phylogeographic analysis of avian influenza viruses isolated from Charadriiformes in Belgium confirms intercontinental reassortment in gulls. Arch Virol 2012, 157:1509-1522.
72. Yu X., Jin T., Cui Y., Pu X., Li J., Xu J. et al. Coexistence of influenza H7N9 and H9N2 in poultry linked to human H7N9 infection and their genome characteristics. J Virol 2014.
73. Clavijo A., Nikooienejad A., Esfahani M.S., Metz R.P., Schwartz S., Atashpaz-Gargari E., et al. Identification and analysis of the first 2009 pandemic H1N1 influenza virus from U. S. feral swine. Zoonoses Public Health 2013, 60:327-335.
74. Lange J., Groth M., Schlegel M., Krumbholz A., Wieczorek K., Ulrich R. et al. Reassortants of the pandemic (H1N1) 2009 virus and establishment of a novel porcine H1N2 influenza virus, lineage in Germany. Vet Microbiol 2013, 167:345-356.
75. Lorusso A., Vincent A.L., Harland M.L., Alt D., Bayles D.O., Swenson S.L., et al. Genetic and antigenic characterization of H1 influenza viruses from United States swine from 2008. J Gen Virol 2011, 92:919-930.
76. Lycett S.J., Baillie G., Coulter E., Bhatt S., Kellam P., McCauley J.W., et al. Estimating reassortment rates in co-circulating Eurasian swine influenza viruses. J Gen Virol 2012, 93:2326-2336.
77. Barrero P.R., Viegas M., Valinotto L.E., Mistchenko A.S. Genetic and phylogenetic analyses of influenza A H1N1pdm virus in Buenos Aires, Argentina. J Virol 2011, 85:1058-1066.
78. de la Rosa-Zamboni D., Vazquez-Perez J.A., Avila-Rios S., Carranco-Arenas A.P., Ormsby C.E., Cummings C.A., et al. Molecular characterization of the predominant influenza A(H1N1)pdm09 virus in Mexico, December 2011-February 2012. PLoS One 2012, 7:e50116.
79. Fordyce S.L., Bragstad K., Pedersen S.S., Jensen T.G., Gahrn-Hansen B., Daniels R., et al. Genetic diversity among pandemic 2009 influenza viruses isolated from a transmission chain. J Virol 2013, 10:116.
80. Lin J., Kang M., Zhong H., Zhang X., Yang F., Ni H. et al. Influenza seasonality and predominant subtypes of influenza virus in Guangdong, China, 2004-2012. J Thorac Dis 2013, 5:S109-S117.
81. Eigen M., Biebricher C.K. Sequence space and quasispecies distribution. RNA Genetics 1988, 211-245. CRC Press, Boca Raton. E. Domingo, E. Domingo, J.J. Holland, J.J. Holland, P. Ahiquist, P. Ahiquist (Eds.).
82. Domingo E., Menendez-Arias L., Quinones-Mateu M.E., Holguin A., Gutierrez-Rivas M., Martinez M.A., et al. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Prog Drug Res 1997, 48:99-128.
83. Najera I., Holguin A., Quinones-Mateu M.E., Munoz-Fernandez M.A., Najera R., Lopez-Galindez C., et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995, 69:23-31.
84. Quinones-Mateu M.E., Holguin A., Dopazo J., Najera I., Domingo E. Point mutant frequencies in the pol gene of human immunodeficiency virus type 1 are two- to threefold lower than those of env. AIDS Res Hum Retroviruses 1996, 12:1117-1128.
85. Gall A., Ferns B., Morris C., Watson S., Cotten M., Robinson M., et al. Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes. J Clin Microbiol 2012, 50:3838-3844.
86. Henn M.R., Boutwell C.L., Charlebois P., Lennon N.J. Power KA, Macalalad AR , et al.Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog 2012, 8:e1002529.
87. Bimber B.N., Dudley D.M., Lauck M., Becker E.A., Chin E.N., Lank S.M. et al. Whole-genome characterization of human and simian immunodeficiency virus intrahost diversity by ultradeep pyrosequencing. J Virol 2010, 84:12087-12092.
88. Fisher R., van Zyl G.U., Travers S.A., Kosakovsky Pond S.L., Engelbrech S., Murrell B., et al. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. J Virol 2012, 86:6231-6237.
89. Hedskog C., Mild M., Jernberg J., Sherwood E., Bratt G., Leitner T. et al. Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One 2010, 5:e11345.
90. Lataillade M., Chiarella J., Yang R., DeGrosky M., Uy J., Seekins D. et al. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing. PLoS One 2012, 7:e30118.
91. Mild M., Hedskog C., Jernberg J., Albert J. Performance of ultra-deep pyrosequencing in analysis of HIV-1 pol gene variation. PloS One 2011, 6:e22741.
92. Mitsuya Y., Varghese V., Wang C., Liu T.F., Holmes S.P., Jayakumar P., et al. Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. J Virol 2008, 82:10747-10755.
93. Mortier V., Dauwe K., Vancoillie L., Staelens D., Van Wanzeele F., Vogelaers D., et al. Frequency and predictors of HIV-1 co-receptor switch in treatment naive patients. PLoS One 2013, 8:e80259.
94. Recordon-Pinson P., Raymond S., Bellecave P., Marcelin A.G., Soulie C., Descamps D., et al. HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication. Antimicrob Agents Chemother 2013, 57:930-935.
95. Rozera G., Abbate I., Bruselles A., Vlassi C., D'Offizi G., Narciso P., et al. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 2009, 6:15.
96. Varghese V., Shahriar R., Rhee S.Y., Liu T., Simen B.B., Egholm M., et al. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2009, 52:309-315.
97. Shao W., Boltz V.F., Spindler J.E., Kearney M.F., Maldarelli F., Mellors J.W., et al. Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of low-frequency drug resistance mutations in HIV-1 DNA. Retrovirology 2013, 10:18.
98. Rozera G., Abbate I., Bruselles A., Vlassi C., D'Offizi G., Narciso P., et al. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 2009, 6:15.
99. Yin L., Liu L., Sun Y., Hou W., Lowe A.C., Gardner B.P., et al. High-resolution deep sequencing reveals biodiversity, population structure, and persistence of HIV-1 quasispecies within host ecosystems. Retrovirology 2012, 9:108.
100. Poon A.F., McGovern R.A., Mo T., Knapp D.J., Brenner B., Routy J.P., et al. Dates of HIV infection can be estimated for seroprevalent patients by coalescent analysis of serial next-generation sequencing data. Aids 2011, 25:2019-2026.
101. Armenia D., Vandenbroucke I., Fabeni L., Van Marck H., Cento V., D'Arrigo R., et al. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis 2012, 205:557-567.
102. Tsibris A.M., Korber B., Arnaout R., Russ C., Lo C.C., Leitner T., et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 2009, 4:e5683.
103. Knoepfel S.A., Di Giallonardo F., Daumer M., Thielen A., Metzner K.J. In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing. J Virol Methods 2011, 171:329-338.
104. Lee G.Q., Swenson L.C., Poon A.F., Martin J.N., Hatano H., Deeks S.G. Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencing. PloS One 2012, 7:e46181.
105. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602.
106. Xiao M., Prabakaran P., Chen W., Kessing B., Dimitrov D.S. Deep sequencing and Circos analyses of antibody libraries reveal antigen-driven selection of Ig VH genes during HIV-1 infection. Exp Mol Pathol 2013, 95:357-363.
107. Zhang Y., Yuan T., Li J., Xu J., Shao Y., Chen Z., et al. The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development. Aids 2013, 27:2529-2539.
108. Brumme C.J., Huber K.D., Dong W., Poon A.F., Harrigan P.R., Sluis-Cremer N. Replication fitness of multiple nonnucleoside reverse transcriptase-resistant HIV-1 variants in the presence of etravirine measured by 454 deep sequencing. J Virol 2013, 87:8805-8807.
109. Ninomiya M., Ueno Y., Funayama R., Nagashima T., Nishida Y., Kondo Y., et al. Use of illumina deep sequencing technology to differentiate hepatitis C virus variants. J Clin Microbiol 2012, 50:857-866.
110. Gregori J., Salicru M., Domingo E., Sanchez A., Rodriguez-Frias F., Quer J. Inference with viral quasispecies diversity indices: Clonal and NGS approaches. Bioinformatics 2014.
111. Escobar-Gutierrez A., Vazquez-Pichardo M., Cruz-Rivera M., Rivera-Osorio P., Carpio-Pedroza J.C., Ruiz-Pacheco J.A., et al. Identification of hepatitis C virus transmission using a next-generation sequencing approach. J Clin Microbiol 2012, 50:1461-1463.
112. Bull R.A., Luciani F., McElroy K., Gaudieri S., Pham S.T., Chopra A., et al. Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog 2011, 7:e1002243.
113. Prokunina-Olsson L., Muchmore B., Tang W., Pfeiffer R.M., Park H., Dickensheets H., et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013, 45:164-171.
114. Hou W., Bonkovsky H.L. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: Dysregulation and implications for early detection, diagnosis and therapy. World J Gastroenterol 2013, 19:7836-7845.
115. Bidzhieva B., Zagorodnyaya T., Karagiannis K., Simonyan V., Laassri M., Chumakov K. Deep sequencing approach for genetic stability evaluation of influenza A viruses. J Virol Methods 2014.
116. Bhatt S., Holmes E.C., Pybus O.G. The genomic rate of molecular adaptation of the human influenza A virus. Mol Biol Evol 2011, 28:2443-2451.
117. Tsai K.N., Chen G.W. Influenza genome diversity and evolution. Microbes Infect 2011, 13:479-488.
118. Warren S., Wan X.F., Conant G., Korkin D. Extreme evolutionary conservation of functionally important regions in H1N1 influenza proteome. PLoS One 2013, 8:e81027.
119. Bourret V., Croville G., Mariette J., Klopp C., Bouchez O., Tiley L., et al. Whole-genome, deep pyrosequencing analysis of a duck influenza A virus evolution in swine cells. Infect Genet Evol 2013, 18:31-41.
120. Crusat M., Liu J., Palma A.S., Childs R.A., Liu Y., Wharton S.A., et al. Changes in the hemagglutinin of H5N1 viruses during human infection-influence on receptor binding. Virology 2013, 447:326-337.
121. Hoper D., Kalthoff D., Hoffmann B., Beer M. Highly pathogenic avian influenza virus subtype H5N1 escaping neutralization: more than HA variation. J Virol 2012, 86:1394-1404.
122. Mertens E., Dugan V.G., Stockwell T.B., Lindsay L.L., Plancarte M., Boyce W.M. Evaluation of phenotypic markers in full genome sequences of avian influenza isolates from California. Comp Immunol Microbiol Infect Dis 2013, 36:521-536.
123. Wilker P.R., Dinis J.M., Starrett G., Imai M., Hatta M., Nelson C.W., et al. Selection on haemagglutinin imposes a bottleneck during mammalian transmission of reassortant H5N1 influenza viruses. Nat Commun 2013, 4:2636.
124. Waybright N., Petrangelo E., Lowary P., Bogan J., Mulholland N. Detection of human virulence signatures in H5N1. J Virol Methods 2008, 154:200-205.
125. Deng Y.M., Caldwell N., Barr I.G. Rapid detection and subtyping of human influenza A viruses and reassortants by pyrosequencing. PLoS One 2011, 6:e23400.
126. Xiao Y.L., Kash J.C., Beres S.B., Sheng Z.M., Musser J.M., Taubenberger J.K. High-throughput RNA sequencing of a formalin-fixed, paraffin-embedded autopsy lung tissue sample from the 1918 influenza pandemic. J Pathol 2013, 229:535-545.
127. Taubenberger J.K. The virulence of the 1918 pandemic influenza virus: unraveling the enigma. Arch Virol Suppl 2005, 101-115.
128. Taubenberger J.K., Reid A.H., Lourens R.M., Wang R., Jin G., Fanning T.G. Characterization of the 1918 influenza virus polymerase genes. Nature 2005, 437:889-893.
129. Tumpey T.M., Basler C.F., Aguilar P.V., Zeng H., Solorzano A., Swayne D.E., et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 2005, 310:77-80.
130. Bartolini B., Chillemi G., Abbate I., Bruselles A., Rozera G., Castrignano T., et al. Assembly and characterization of pandemic influenza A H1N1 genome in nasopharyngeal swabs using high-throughput pyrosequencing. New Microbiol 2011, 34:391-397.
131. Deyde V.M., Gubareva L.V. Influenza genome analysis using pyrosequencing method: current applications for a moving target. Expert Rev Mol Diagn 2009, 9:493-509.
132. Hoper D., Hoffmann B., Beer M. A comprehensive deep sequencing strategy for full-length genomes of influenza A. PLoS One 2011, 6:e19075.
133. Kampmann M.L., Fordyce S.L., Avila-Arcos M.C., Rasmussen M., Willerslev E., Nielsen L.P., et al. A simple method for the parallel deep sequencing of full influenza A genomes. J Virol Methods 2011, 178:243-248.
134. Rutvisuttinunt W., Chinnawirotpisan P., Simasathien S., Shrestha S.K., Yoon I.K., Klungthong C., et al. Simultaneous and complete genome sequencing of influenza A and B with high coverage by Illumina MiSeq platform. J Virol Methods 2013, 193:394-404.
135. Hoper D., Hoffmann B., Beer M. Simple, sensitive, and swift sequencing of complete H5N1 avian influenza virus genomes. J Clin Microbiol 2009, 47:674-679.
136. Ren X., Yang F., Hu Y., Zhang T., Liu L., Dong J., et al. Full genome of influenza A (H7N9) virus derived by direct sequencing without culture. Emerg Infect Dis 2013, 19:1881-1884.
137. Archer J., Baillie G., Watson S.J., Kellam P., Rambaut A., Robertson D.L. Analysis of high-depth sequence data for studying viral diversity: a comparison of next generation sequencing platforms using Segminator II. BMC Bioinformatics 2012, 13:47.
138. Flaherty P., Natsoulis G., Muralidharan O., Winters M., Buenrostro J., Bell J., et al. Ultrasensitive detection of rare mutations using next-generation targeted resequencing. Nucleic Acids Res 2012, 40:e2.
139. Kuroda M., Katano H., Nakajima N., Tobiume M., Ainai A., Sekizuka T., et al. Characterization of quasispecies of pandemic 2009 influenza A virus (A/H1N1/2009) by de novo sequencing using a next-generation DNA sequencer. PLoS One 2010, 5:e10256.
140. Levine M., Sheu T.G., Gubareva L.V., Mishin V.P. Detection of hemagglutinin variants of the pandemic influenza A (H1N1) 2009 virus by pyrosequencing. J Clin Microbiol 2011, 49:1307-1312.
141. Watson S.J., Welkers M.R., Depledge D.P., Coulter E., Breuer J.M., de Jong M.D., et al. Viral population analysis and minority-variant detection using short read next-generation sequencing. Philos Trans R Soc Lond B Biol Sci 2013, 368:20120205.
142. Kwong A.D., Najera I., Bechtel J., Bowden S., Fitzgibbon J., Harrington P., et al. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG. Gastroenterology 2011, 140:755-760.
143. Shafer R.W. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 2006, 194(Suppl 1):S51-S58.
144. Larder B.A., Kohli A., Kellam P., Kemp S.D., Kronick M., Henfrey R.D. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993, 365:671-673.
145. Church J.D., Jones D., Flys T., Hoover D., Marlowe N., Chen S. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103 N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn 2006, 8:430-432. quiz 527.
146. Halvas E.K., Aldrovandi G.M., Balfe P., Beck I.A., Boltz V.F., Coffin J.M., et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 2006, 44:2612-2614.
147. Leitner T., Halapi E., Scarlatti G., Rossi P., Albert J., Fenyo E.M., et al. Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques 1993, 15:120-127.
148. Grant R.M., Kuritzkes D.R., Johnson V.A., Mellors J.W., Sullivan J.L., Swanstrom R., et al. Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol 2003, 41:1586-1593.
149. Dudley D.M., Chin E.N., Bimber B.N., Sanabani S.S., Tarosso L.F., Costa P.R., et al. Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One 2012, 7:e36494.
150. Fisher R., van Zyl G.U., Travers S.A., Kosakovsky Pond S.L., Engelbrech S., Murrell B., et al. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. J Virol 2012, 86:6231-6237.
151. Simen B.B., Simons J.F., Hullsiek K.H., Novak R.M., Macarthur R.D., Baxter J.D., et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009, 199:693-701.
152. Wang C., Mitsuya Y., Gharizadeh B., Ronaghi M., Shafer R.W. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 2007, 17:1195-1201.
153. Gibson R.M., Meyer A.M., Winner D., Archer J., Feyertag F., Ruiz-Mateos E., et al. Sensitive deep sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1coreceptor tropism. Antimicrob Agents Chemother 2014, 58:2167-2185.
154. Avidor B., Girshengorn S., Matus N., Talio H., Achsanov S., Zeldis I., et al. Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory. J Clin Microbiol 2013, 51:880-886.
155. Stelzl E., Proll J., Bizon B., Niklas N., Danzer M., Hackl C., et al. Human immunodeficiency virus type 1 drug resistance testing: evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit. J Virol Methods 2011, 178:94-97.
156. Willerth S.M., Pedro H.A., Pachter L., Humeau L.M., Arkin A.P., Schaffer D.V. Development of a low bias method for characterizing viral populations using next generation sequencing technology. PLoS One 2010, 5:e13564.
157. Chang M.W., Oliveira G., Yuan J., Okulicz J.F., Levy S., Torbett B.E. Rapid deep sequencing of patient-derived HIV with ion semiconductor technology. J Virol Methods 2013, 189:232-234.
158. Ji H., Li Y., Graham M., Liang B.B., Pilon R., Tyson S., et al. Next-generation sequencing of dried blood spot specimens: a novel approach to HIV drug-resistance surveillance. Antivir Ther 2011, 16:871-878.
159. Ji H., Li Y., Liang B., Pilon R., MacPherson P., Bergeron M., et al. Pyrosequencing dried blood spots reveals differences in HIV drug resistance between treatment naive and experienced patients. PLoS One 2013, 8:e56170.
160. Bellecave P., Recordon-Pinson P., Papuchon J., Vandenhende M.A., Reigadas S., Tauzin B., et al. Detection of Low-Frequency HIV Type 1 Reverse Transcriptase Drug Resistance Mutations by Ultradeep Sequencing in Naive HIV Type 1-Infected individuals. AIDS Res Hum Retroviruses 2013.
161. Gonzalez S., Tully D.C., Gondwe C., Wood C. Low-abundance resistant mutations in HIV-1 subtype C antiretroviral therapy-naive individuals as revealed by pyrosequencing. Curr HIV Res 2013, 11:43-49.
162. Ji H., Liang B., Li Y., Van Domselaar G., Graham M., Tyler S., et al. Low abundance drug resistance variants in transmitted HIV drug resistance surveillance specimens identified using tagged pooled pyrosequencing. J Virol Methods 2013, 187:314-320.
163. Lataillade M., Chiarella J., Yang R., Schnittman S., Wirtz V., Uy J., et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS One 2010, 5:e10952.
164. Messiaen P., Verhofstede C., Vandenbroucke I., Dinakis S., Van Eygen V., Thys K., et al. Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients. Virology 2012, 426:7-11.
165. Simen B.B., Simons J.F., Hullsiek K.H., Novak R.M., Macarthur R.D., Baxter J.D., et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009, 199:693-701.
166. Geretti A.M., Conibear T., Hill A., Johnson J.A., Tambuyzer L., Thys K., et al. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz. J Antimicrob Chemother 2013.
167. Li J.Z., Paredes R., Ribaudo H.J., Svarovskaia E.S., Kozal M.J., Hullsiek K.H., et al. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 2012, 26:185-192.
168. Li J.Z., Kuritzkes D.R. Clinical implications of HIV-1 minority variants. Clin Infect Dis 2013, 56:1667-1674.
169. Li J.Z., Paredes R., Ribaudo H.J., Svarovskaia E.S., Metzner K.J., Kozal M.J., et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011, 305:1327-1335.
170. Stekler J.D., Ellis G.M., Carlsson J., Eilers B., Holte S., Maenza J., et al. Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PloS One 2011, 6:e28952.
171. Li J.Z., Paredes R., Ribaudo H.J., Kozal M.J., Svarovskaia E.S., Johnson J.A., et al. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. The Journal of infectious diseases 2013, 207:893-897.
172. Codoner F.M., Pou C., Thielen A., Garcia F., Delgado R., Dalmau D., et al. Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. PLoS One 2011, 6:e19461.
173. Gonzalez S., Tully D.C., Gondwe C., Wood C. Low-abundance resistant mutations in HIV-1 subtype C antiretroviral therapy-naive individuals as revealed by pyrosequencing. Curr HIV Res 2013, 11:43-49.
174. Beerenwinkel N., Gunthard H.F., Roth V., Metzner K.J. Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data. Front Microbiol 2012, 3:329.
175. Sarrazin C., Hezode C., Zeuzem S., Pawlotsky J.M. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012, 56(Suppl 1):S88-S100.
176. Scheel T.K., Rice C.M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013, 19:837-849.
177. Pawlotsky J.M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53:1742-1751.
178. Franco S., Bellido R., Aparicio E., Canete N., Garcia-Retortillo M., Sola R., et al. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors. J Viral Hepat 2011, 18:e578-e582.
179. Aparicio E., Franco S., Parera M., Andres C., Tural C., Clotet B., et al. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients. J Virol 2011, 85:5961-5969.
180. Bartolini B., Giombini E., Zaccaro P., Selleri M., Rozera G., Abbate I., et al. Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients. Virus Res 2013, 177:205-208.
181. Nasu A., Marusawa H., Ueda Y., Nishijima N., Takahashi K., Osaki Y., et al. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS One 2011, 6:e24907.
182. Franco S., Casadella M., Noguera-Julian M., Clotet B., Tural C., Paredes R., et al. No detection of the NS5B S282T mutation in treatment-naive genotype 1HCV/HIV-1 coinfected patients using deep sequencing. J Clin Virol 2013, 58:726-729.
183. Chevaliez S., Rodriguez C., Soulier A., Ahmed-Belkacem A., Hezode C., Pawlostky J.M. Molecular characterization of hepatitis C virus resistance to telaprevir by means of ultra-deep pyrosequencing. 18th International Symposium on HCV and related viruses 2011.
184. Svarovskaia E.S., Martin R., McHutchison J.G., Miller M.D., Mo H. Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy. J Clin Microbiol 2012, 50:3267-3274.
185. Bao J.R., Huard T.K., Piscitelli A.E., Tummala P.R., Aleemi V.E., Coon S.L., et al. Reverse-transcription polymerase chain reaction/pyrosequencing to characterize neuraminidase H275 residue of influenza A 2009H1N1 virus for rapid and specific detection of the viral oseltamivir resistance marker in a clinical laboratory. Diagn Microbiol Infect Dis 2011, 71:396-402.
186. Chantratita W., Sukasem C., Sirinavin S., Sankuntaw N., Srichantaratsamee C., Pasomsub E., et al. Simultaneous detection and subtyping of H274Y-positive influenza A (H1N1) using pyrosequencing. J Infect Dev Ctries 2011, 5:348-352.
187. Deng Y.M., Caldwell N., Hurt A., Shaw T., Kelso A., Chidlow G., et al. A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses. Antiviral Res 2011, 90:87-91.
188. Deyde V.M., Nguyen T., Bright R.A., Balish A., Shu B., Lindstrom S., et al. Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method. Antimicrob Agents Chemother 2009, 53:1039-1047.
189. Deyde V.M., Okomo-Adhiambo M., Sheu T.G., Wallis T.R., Fry A., Dharan N., et al. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res 2009, 81:16-24.
190. Duan S., Boltz D.A., Li J., Oshansky C.M., Marjuki H., Barman S., et al. Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis. Antimicrob Agents Chemother 2011, 55:4718-4727.
191. Duwe S., Schweiger B. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J Virol Methods 2008, 153:134-141.
192. Gubareva L.V., Trujillo A.A., Okomo-Adhiambo M., Mishin V.P., Deyde V.M., Sleeman K., et al. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther 2010, 15:1151-1159.
193. Lackenby A., Democratis J., Siqueira M.M., Zambon M.C. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir Ther 2008, 13:809-820.
194. Mok C.K., Chang S.C., Chen G.W., Lo Y.L., Chen S.J., Wu H.S., et al. Pyrosequencing reveals an oseltamivir-resistant marker in the quasispecies of avian influenza A (H7N9) virus. J Microbiol Immunol Infect 2013.
195. Okomo-Adhiambo M., Sheu T.G., Gubareva L.V. Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors. Influenza Other Respir Viruses 2013, 7(Suppl 1):44-49.
196. Operario D.J., Moser M.J., St George K. Highly sensitive and quantitative detection of the H274Y oseltamivir resistance mutation in seasonal A/H1N1 influenza virus. J Clin Microbiol 2010, 48:3517-3524.
197. Qi Y., Fan H., Qi X., Zhu Z., Guo X., Chen Y., et al. A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus. Virus Res 2013.
198. Tamura D., Nguyen H.T., Sleeman K., Levine M., Mishin V.P., Yang H., et al. Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment. Antimicrob Agents Chemother 2013, 57:6141-6146.
199. Whitehead T.A., Chevalier A., Song Y., Dreyfus C., Fleishman S.J., De Mattos C., et al. Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nat Biotechnol 2012, 30:543-548.
200. Wu N.C., Young A.P., Dandekar S., Wijersuriya H., Al-Mawsawi L.Q., Wu T.T., et al. Systematic identification of H274Y compensatory mutations in influenza A virus neuraminidase by high-throughput screening. J Virol 2013, 87:1193-1199.
201. Okomo-Adhiambo M., Nguyen H.T., Sleeman K., Sheu T.G., Deyde V.M., Garten R.J., et al. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res 2010, 85:381-388.
202. Dharan N.J., Fry A.M., Kieke B.A., Coleman L., Meece J., Vandermause M., et al. Clinical and virologic outcomes in patients with oseltamivir-resistant seasonal influenza A (H1N1) infections: results from a clinical trial. Influenza Other Respir Viruses 2012, 6:153-158.
203. Ghedin E., Holmes E.C., DePasse J.V., Pinilla L.T., Fitch A., Hamelin M.E., et al. Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission. J Infect Dis 2012, 206:1504-1511.
204. Inoue M., Barkham T., Leo Y.S., Chan K.P., Chow A., Wong C.W., et al. Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48hours. Emerg Infect Dis 2010, 16:1633-1636.
205. Tellez-Sosa J., Rodriguez M.H., Gomez-Barreto R.E., Valdovinos-Torres H., Hidalgo A.C., Cruz-Hervert P., et al. Using high-throughput sequencing to leverage surveillance of genetic diversity and oseltamivir resistance: a pilot study during the 2009 influenza A(H1N1) pandemic. PLoS One 2013, 8:e67010.
206. Englund J., Zerr D., Heath J., Pergam S., Kuypers J., Yager J., et al. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 2009, 58:893-896.
207. Garrison M., Weldon L., Brantley P., Wolf L., Davies M., Maillard J.-M., et al. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009, 58:969-972.
208. Arvia R., Corcioli F., Simi L., Orlando C., De Santis R., Facchini M., et al. Monitoring the susceptibility to oseltamivir of influenza A(H1N1) 2009 virus by nested-PCR and pyrosequencing during the pandemic and in the season 2010-2011. J Virol Methods 2012, 184:113-116.
209. Chen L.F., Dailey N.J., Rao A.K., Fleischauer A.T., Greenwald I., Deyde V.M., et al. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients-North Carolina, 2009. J Infect Dis 2011, 203:838-846.
210. Correia V., de Andrade H.R., Santos L.A., Lackenby A., Zambon M. Antiviral drug profile of seasonal influenza viruses circulating in Portugal from 2004/2005 to 2008/2009 winter seasons. Antiviral Res 2010, 86:128-136.
211. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009, 301:1034-1041.
212. Duwe S.C., Wedde M., Birkner P., Schweiger B. Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany. Antiviral Res 2011, 89:115-118.
213. Eshaghi A., Bolotin S., Burton L., Low D.E., Mazzulli T., Drews S.J. Genetic microheterogeneity of emerging H275Y influenza virus A (H1N1) in Toronto, Ontario, Canada from the 2007-2008 respiratory season. J Clin Virol 2009, 45:142-145.
214. Hoang Vu M.P., Nguyen C.T., Nguyen le K.H., Nguyen T.K., Le Q.M. Oseltamivir resistance among influenza viruses: surveillance in northern Viet Nam 2009-2012. Western Pac Surveill Response J 2013, 4:25-29.
215. Hurt A.C., Ernest J., Deng Y.M., Iannello P., Besselaar T.G., Birch C., et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009, 83:90-93.
216. Longtin J., Patel S., Eshaghi A., Lombos E., Higgins R., Alexander D., et al. Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada. J Clin Virol 2011, 50:257-261.
217. Miller H.B., Gose R.B., Nagata M.T., Sciulli R.H., Whelen A.C. Pacific region influenza surveillance for oseltamivir resistance. J Clin Virol 2012, 54:73-75.
218. Nguyen H.T., Trujillo A.A., Sheu T.G., Levine M., Mishin V.P., Shaw M., et al. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States. Antiviral Res 2012, 93:381-386.
219. Okomo-Adhiambo M., Demmler-Harrison G.J., Deyde V.M., Sheu T.G., Xu X., Klimov A.I., et al. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother 2010, 54:1834-1841.
220. Pontoriero A., Baumeister E., Campos A.M., Savy V.L. Virological surveillance and antiviral resistance of human influenza virus in Argentina, 2005-2008. Rev Panam Salud Publica 2011, 30:634-640.
221. Esposito S., Molteni C.G., Daleno C., Valzano A., Fossali E., Da Dalt L., et al. Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy. J Virol 2010, 7:202.
222. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005, 366:1175-1181.
223. Bright R.A., Shay D.K., Shu B., Cox N.J., Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006, 295:891-894.
224. Deyde V.M., Xu X., Bright R.A., Shaw M., Smith C.B., Zhang Y., et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007, 196:249-257.
225. Higgins R.R., Eshaghi A., Burton L., Mazzulli T., Drews S.J. Differential patterns of amantadine-resistance in influenza A (H3N2) and (H1N1) isolates in Toronto, Canada. J Clin Virol 2009, 44:91-93.
226. Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC- CKR-5. Nature 1996, 381:667-673.
227. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
228. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
229. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49:4721-4732.
230. Rose J.D., Rhea A.M., Weber J., Quinones-Mateu M.E. Current tests to evaluate HIV-1 coreceptor tropism. Curr Opin HIV AIDS 2009, 4:136-142.
231. Poveda E., Briz V., Quinones-Mateu M., Soriano V. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006, 20:1359-1367.
232. Weber J., Piontkivska H., Quinones-Mateu M.E. HIV type 1 tropism and inhibitors of viral entry: clinical implications. AIDS Rev 2006, 8:60-77.
233. Whitcomb J.M., Huang W., Fransen S., Limoli K., Toma J., Wrin T., et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007, 51:566-575.
234. Reeves J.D., Coakley E., Petropoulos C.J., Whitcomb J.M. An enhanced-sensitivity Trofile™ HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J Viral Entry 2009, 3:94-102.
235. Obermeier M., Symons J., Wensing A.M. HIV population genotypic tropism testing and its clinical significance. Curr Opin HIV AIDS 2012, 7:470-477.
236. Poveda E., Alcami J., Paredes R., Cordoba J., Gutierrez F., Llibre J.M., et al. Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev 2010, 12:135-148.
237. Swenson L.C., Mo T., Dong W.W., Zhong X., Woods C.K., Thielen A., et al. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 2011, 53:732-742.
238. Swenson L.C., Mo T., Dong W.W., Zhong X., Woods C.K., Jensen M.A., et al. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 2011, 203:237-245.
239. Saliou A., Delobel P., Dubois M., Nicot F., Raymond S., Calvez V., et al. Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob Agents Chemother 2011, 55:2831-2836.
240. Kagan R.M., Johnson E.P., Siaw M.F., Van Baelen B., Ogden R., Platt J.L., et al. Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of cenicriviroc study 202, a randomized phase II trial in treatment-naive subjects. AIDS Res Hum Retroviruses 2013, 30:151-159.
241. Kagan R.M., Johnson E.P., Siaw M., Biswas P., Chapman D.S., Su Z., et al. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients. PLoS One 2012, 7:e46334.
242. Swenson L.C., Moores A., Low A.J., Thielen A., Dong W., Woods C., et al. Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr 2010, 54:506-510.
243. Swenson L.C., Daumer M., Paredes R. Next-generation sequencing to assess HIV tropism. Curr Opin HIV AIDS 2012, 7:478-485.
244. Archer J., Braverman M.S., Taillon B.E., Desany B., James I., Harrigan P.R., et al. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 2009, 23:1209-1218.
245. Vandenbroucke I., Van Marck H., Mostmans W., Van Eygen, Rondelez E., Thys K., et al. HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays. AIDS Res Ther 2010, 7:4.
246. Archer J., Rambaut A., Taillon B.E., Harrigan P.R., Lewis M., Robertson D.L. The evolutionary analysis of emerging low frequency HIV-1CXCR4 using variants through time-an ultra-deep approach. PLoS Comput Biol 2010, 6:e1001022.
247. Raymond S., Saliou A., Nicot F., Delobel P., Dubois M., Cazabat M., et al. Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencing. AIDS 2011, 25:1668-1670.
248. Abbate I., Vlassi C., Rozera G., Bruselles A., Bartolini B., Giombini E., et al. Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection. AIDS 2011, 25:611-617.
249. Lee G.Q., Harrigan P.R., Dong W., Poon A.F., Heera J., Demarest J., et al. Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original trofile assay in non-B subtypes. AIDS Res Hum Retroviruses 2013, 29:979-984.
250. Bunnik E.M., Swenson L.C., Edo-Matas D., Huang W., Dong W., Frantzell A., et al. Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS Pathog 2011, 7:e1002106.
251. Rozera G., Abbate I., Bruselles A., Vlassi C., D'Offizi G., Narciso P., et al. Archived HIV-1 minority variants detected by ultra-deep pyrosequencing in provirus may be fully replication competent. AIDS 2009, 23:2541-2543.
252. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011, 28:2731-2739.